Skip to main content
Skip to main content
Normal View Dyslexic View

Author response: Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study

BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
_______
BJS, https://doi.org/10.1093/bjs/znae178, published 30 August 2024
_______
Dear Editor
Thank you to our colleagues for their kind letter and the attention they have given to our article, “Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study.” 1 We truly appreciate the time and effort they dedicated to discussing our work in their Journal Club.
In this study, we chose not to include patients with functioning tumors to maintain a homogeneous study population. Functionality was excluded clinically, based on the absence of symptoms suggestive of hormone hypersecretion in the patients’ medical history and clinical evaluation. However, we did not perform specific hormonal tests to exclude tumor secretion.
Looking ahead, we do not consider the presence of a syndrome associated with a functioning pancreatic neuroendocrine tumor to be a contraindication to neoadjuvant 177Lu-DOTATATE therapy. That said, such cases are likely to remain rare. Insulinomas, for example, are typically small and easily resectable, while other functioning forms are extremely uncommon.
The question regarding surgical challenges following neoadjuvant therapy is particularly insightful. One of our initial concerns was the potential for post-treatment fibrotic reactions to complicate surgery. While we observed cases of fibrosis that made surgery more challenging in our earlier experience, no significant surgical difficulties related to fibrosis were encountered in this study.
It is also worth noting that the observed rate of pancreatic fistula, consistent with the expected rates for the type of surgery and pathology, suggests that fibrosis—known to lower the risk of fistulas—was not particularly evident in this study.
We hope this response addresses their thoughtful inquiries. We thank them once again for their interest in our study and for fostering this meaningful academic exchange.
References
Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U et al. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. BJS 2024;111; doi: https://doi.org/10.1093/bjs/znae178.
Copied!